Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine

Vaccine

Volumn 22, Issue 17-18, 2004, Pages 2234-2243

  Borja Cabrera, Gulnara Patricia ^a   Mendes, Amanda Cruz ^a   Paraguai De Souza, Edilma ^a   Okada, Lilian Y Hashimoto ^b   Trivellato, Fernando Antonio De A ^b   Kawasaki, Jarbas Kiyoshi A ^b   Costa, Andreia Cerqueira ^b   Reis, Alexandre Barbosa ^c,d   Genaro, Odair ^d   Batista, Leopoldina Maria Melo ^e   Palatnik, Marcos ^a   Palatnik De Sousa, Clarisa Beatriz ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Clin Vet de Caes de Gatos   (Brazil)

^c FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^e Centro de Controle de Zoonoses   (Brazil)

Author keywords

Canine visceral leishmaniasis; Fucose mannose ligand; Immunochemotherapy; Immunotherapy; Kala azar; Saponin; Vaccine; Zoonoses

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; FUCOSE MANNOSE LIGAND VACCINE; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2 ANTIBODY; LEISHMANIA VACCINE; SAPONIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANINE VISCERAL LEISHMANIASIS; CLINICAL FEATURE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DOG; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EXPERIMENT; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNOTHERAPY; LEISHMANIA CHAGASI; LEISHMANIA DONOVANI; LEISHMANIASIS; LYMPHOCYTE; NONHUMAN; PARASITE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTECTION; RECORDING; SEROLOGY; SYMPTOMATOLOGY; VACCINATION;

EID: 2442716621     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.11.039     Document Type: Article

References (50)

1. Tesh R. Control of zoonotic visceral leishmaniasis. Is it time to change strategies. Am. J. Trop. Med. Hyg. 52:1995;287-292
2. Palatnik-de-Sousa C.B., Santos W.R., França-Silva J.C., da Costa R.T., Barbosa Reis A., Palatnik M., et al. Impact of canine control on the epidemiology of canine and human visceral leishmaniasis in Brazil. Am. J. Trop. Med. Hyg. 65:2001;510-517
3. Alvar J., Molina R., San Andrés M., Tesouro M., Nieto J., Vitutia M., et al. Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy. Ann. Trop. Med. Parasitol. 88:1994;371-378
4. Ranque J., Ranque M., Cabassu J., Cabassu H. Le diagnostic précoce de la leishmaniose canine par la ponction ganglionnaire. Réflexions à propos de soixante examens positifs obtenus en dix mois dans la région Marsellaise. Bull. Acad. Nat. Med. 132:1948;339-340
5. Marzochi M.C.A., Coutinho S.G., Souza W.J.S., Toledo L.M., Grimaldi G. Jr., Momen H., et al. Canine visceral leishmaniasis in Rio de Janeiro, Brazil. Clinical, parasitological, therapeutical and epidemiological findings (1977-1983). Mem. Inst. Osw. Cruz. 80:1985;349-357
6. Oliva G., Gradoni L., Cortese L., Orsini S., Ciaramella P., Scalone A., et al. Comparative efficacy of meglumine antimoniate and aminosidine sulphate, alone or in combination, in canine leishmaniasis. Ann. Trop. Med. Parasitol. 92:1998;165-171
7. Lanotte G., Rioux J.Á., Pereires J., Vollhardt Y. Ecologie des leishmanioses dans le sud de la France. 10. Les formes évolutives de la leishmaniose viscérale canine. Elaboration d'une typologie bio-clinique à finalité épidémiologique. Ann. Parasitol. 54:1979;277-295
8. Von Reiter I., Kretzschmar A., Boch J., Krampitz H. Zur leishmaniose des hundes. Infektionsverlauf, diagnose un therapieversuche nach exp. Infection vom Beagles mit Leishmania donovani (st. Kalkutta). Berl. Münc. Tierärztl. Wschr. 98:1985;40-44
9. Organização Mundial da Saúde. Lucha contra las leishmanioses. Serie de informes técnicos 1990;793:1-177.
10. Gradoni L., Maroli M., Gramiccia M., Mancianti F. Leishmania infantum infection rates in Phlebotomus perniciosus fed on naturally infected dogs under antimonial treatment. Med. Vet. Entomol. 1:1987;339-342
11. World Health Organization-TDR. The TDR 15th programm report. Research Progress 1999-2000. New and Improved Tools; 2003. http://www.who.int/tdr/ research/progress9900/tools/vdr.htm.
12. Modabber, F. Leishmaniasis. In: Tropical disease research progress, 1991-1992. Geneva: World Health Organization; 1993. p. 77-87.
13. Dunan S., Frommel D., Monjour L., Ogunkolade B.W., Cruz A., Quilici M. Vaccination trial against canine visceral leishmaniasis. Parasite Immunol. 11:1989;397-402
14. Mayrink W., Genaro O., Franca-Silva J.C., Costa R.T., Tafuri L., Toledo V.P.C.P., et al. Phase I and II open clinical trials of a vaccine against Leishmania chagasi infections in dogs. Mem. Inst. Osw. Cruz. MEMIOC. 91:1996;695-697
15. Antunes C.M., Mayrink W., Magalhães P.A., Costa A., Melo M.N., Dias M., et al. Controlled field trials of a vaccine against new world cutaneous leishmaniasis. Int. J. Epidemiol. 15:1986;572-580
16. Genaro O., Pinto J.A., da Costa C.A., França Silva J.C., Costa R.T., Silva J.C., et al. Phase III randomized double blind clinical trial of the efficacy of a vaccine against canine visceral leishmaniasis in urban area of Montes Claros, MG. Braz. Mem. Inst. Osw. Cruz. MEMIOC. 91:1996;166
17. Ramiro M.J., Zárate J.J., Hanke T., Rodriguez D., Rodriguez J.R., Esteban M., et al. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA vaccine and vaccinia recombinant vectors expresssing LACK. Vaccine. 21:2003;2474-2484
18. da Silva V.O., Borja-Cabrera G.P., Correia Pontes N.N., Paraguai de Souza E., Luz K.G., Palatnik M., et al. A Phase III trial of Efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil(São Gonçalo do Amarante, RN). Vaccine. 19:2001;1082-1092
19. Borja-Cabrera G.P., Correia Pontes N.N., da Silva V.O., Paraguai de Souza E., Santos W.R., Gomes E.M., et al. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante). Vaccine. 20:2002;3277-3284
20. Mendes C.O., Paraguai de Souza E., Borja-Cabrera G.P., Melo Batista L.M., Santos M.A., Parra L.E., et al. IgG1/IgG2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral leishmaniasis. Vaccine. 21(19/20):2003;2589-2597
21. Palatnik C.B., Borojevic R., Previato J.O., Mendonça-Previato L. Inhibition of Leishmania donovani promastigote internalization into murine macrophages by chemically defined parasite glycoconjugate. Infect. Immun. 57:1989;754-763
22. Palatnik de Sousa C.B., Dutra H.S., Borojevic R. Leishmania donovani surface glycoconjugate GP36 is the major immunogen component of the fucose-mannose ligand (FML). Acta Trop. 53:1993;59-72
23. Santos W.R., Paraguai de Souza E., Palatnik M., Palatnik de Sousa C.B. Vaccination with the FML antigen (fucose mannose ligand) of Leishmania donovani in the Swiss Albino model. Vaccine. 17:1999;2554-2561
24. Santos W.R., de Lima V.M.F., Paraguai de Souza E., Bernardo R.R., Palatnik M., Palatnik de Sousa C.B. Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Vaccine. 21:2002;30-43
25. Palatnik de Sousa C.B., Gomes E.M., Paraguai de Souza E., Luz K., Palatnik M., Borojevic R. Leishmania donovani: titration of antibodies to the fucose mannose ligand as an aid in diagnosis and prognosis of visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 89:1995;390-393
26. Borja Cabrera G.P., da Silva V.O., da Costa R.T., Barbosa Reis A., Mayrink W., Genaro O., et al. The FML-ELISA assay in diagnosis and prognosis of canine visceral leishmaniasis. Am. J. Trop. Med. Hyg. 61:1999;296-301
27. Palatnik de Sousa C.B., Paraguai de Souza E., Gomes E.M., Borojevic R. Experimental murine Leishmania donovani infection: Immunoprotection by the fucose mannose ligand (FML). Braz. J. Med. Biol. Res. 27:1994;547-551
28. Palatnik de Sousa C.B., Moreno M.B., Paraguai de Souza E., Borojevic R. The FML vaccine (fucose-mannose ligand) protects hamsters from experimental Kala-Azar. Ciência e Cultura (J. Braz. Assoc. Adv. Sci.). 46:1994;290-296
29. Badaró R., Chun P., Nakatani M., Burns J., Skeiky Y., Hougton R., et al. TRALd - A rapid test specific for serodiagnosis of visceral leishmanioses. Acta Parasitol. Tur. 21(Suppl 1):1997;175
30. Santos W.R., Aguiar I.A., Paraguai de Souza E., de Lima V.F.M., Palatnik M., Palatnik-de-Sousa C.B. Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine. Vaccine. 21(32):2003;4668-4676
31. Ranque JM, Quilici M, Dunan S. Les leishmanioses de la region provençale. Considerations epidemiologiques et ecologiques. Colloques Internationaux du CNRS. Ecologie des leishmanioses. Paris: Centre National de la Recherche Scientifique. 1977;239:285-93.
32. Abranches P., Silva-Pereira M.C.D., Conceição-Silva F.M., Santana-Gomes G.M., Janz J.G. Canine leishmaniasis: pathological and ecological factors influencing trasmission of infection. J. Parasitol. 77(4):1991;557-561
33. da Costa R.T., Genaro O., França-Silva J.C., da Costa C.A., Mayrink W. Urban visceral leishmaniasis in Minas Gerais: a picture about the infection in dogs attended in veterinarian clinics in the metropolitan area of Belo Horizonte and Montes Claros, MG. Mem. Inst. Osw. Cruz. 91(Suppl):1996;154
34. Fisher RA, Yates F. Student's t-test of significance. In: Statistical tables for agricultural, biological and other research workers. Edinburgh: Oliver and Boyd; 1957. p. 157.
35. Guarga J.L., Moreno J., Lucientes J., Gracia M.J., Peribanez M.A., Alvar J., et al. Canine leishmaniasis transmission: higher infectivity among naturally infected dogs to sandflies is associated with lower proportions of T helper cells. Res. Vet. Sci. 69:2000;249-253
36. Bourdoiseau G., Bonnefont C., Hoareau E., Boehringer C., Stolle T., Chabanne L. Specific IgG1 and IgG2 antibody and lymphocyte subset levels in naturally Leishmania infantum-infected treated and untreated dogs. Vet. Immunopathol. 59:1997;21-30
37. Moreno J., Nieto J., Chamizo C., Gonzalez F., Blanco F., Barker F., et al. The immune response and PBMC subsets in canine visceral leishmaniasis before and after chemoterapy. Vet. Immunopathol. 30:1999;181-195
38. Guarga J.L., Moreno J., Lucientes J., Gracia M.J., Peribáñez M.A., Castillo J.Á. Evaluation of a specific immunochemotherapy for the treatment of canine visceral leishmaniasis. Vet. Immunol. Immunopathol. 88:2002;13-20
39. Marciani D.J., Press J.B., Eynolds R.C., Pathak A.K., Pathak V., Gundy L.E., et al. Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity. Vaccine. 18:2000;3141-3151
40. Courtenay O., Quinnell R.J., Garcez L.M., Shaw J.J., Dye C. Infectiousness in a cohort of Brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission. J. Infect. Dis. 186:2002;1314-1320
41. Genaro O, da Costa RT, França-Silva JC, Reis AB, Silva JC, Vieira EP, et al. Evaluation of an immunochromatographic assay for the diagnosis of dogs experimentally and naturally infected with Leishmania chagasi in Brazil. Acta Parasitol Tur (Suppl I);1996:93.
42. Molano I., García Alonso M., Mirón C., Redondo E., Requena J.M., Soto M., et al. A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum. Vet. Immunol. Immunopathol. 92:2003;1-13
43. Carrera L., Fermín M.L., Tesouro M., García P., Rollán E., González J.L., et al. Antibody rersponse in dogs experimentally infected with Leishmania infantum: infection course antigen markers. Exp. Parasitol. 82:1996;139-146
44. Pinelli E., Killick-Kendrick R., Wagennar E., Bernadina W., del Real G., Ruitenberg J. Cellular and humoral immune responses in dogs experimentally and naturally infectes with Leishmania (L.) infantum. Infect. Immunol. 62:1994;229-235
45. Borja-Cabrera GP. Análise do potencial diagnóstico, prognóstico e imunoprotetor do antígeno FML (ligante de fucose manose) de Leishmania (L.) donovani, no calazar canino experimental e de área endêmica. Ph.D. thesis. Department of Experimental Pathology, Federal Fluminense University; 2000. p:79.
46. Cardoso L., Cabral M. Leishmania and canine leishmanioses. Rev. Port. Cien. Vet. 527:1998;121-141
47. Solano-Gallego L., Riera C., Roura X., Inieste L., Gallego M., Valladares J.E., et al. Leishmania infantum-specific IgG, IgG1 and IgG2 antibody responses in healthy and ill dogs from endemic areas. Evolution in the course of infection and after treatment. Vet. Parasitol. 96:2001;265-276
48. Deplazes P., Smith N.C., Arnold P., Lutz H., Eckert J. Specific IgG1 and IgG2 antibody responses of dogs to Leishmania infantum and other parasites. Parasite Immunol. 17:1995;451-458
49. Altet L., Francino O., Solano-Gallego L., Renier C., Sanchez A. Mapping and sequencing of the canine NRAMP1 gene and identification of mutations in leishmaniasis-susceptible dogs. Infect. Immun. 70:2002;2763-2771
50. Mayrink W., Genaro O., Costa C.A., França-Silva J.C., Hermeto M.V., Oliveira Lima A. Combined immunotherapy and chemotherapy in canine visceral leishmaniasis. Preliminary findings. Mem. Inst. Osw. Cruz. 87(Suppl 2):1992;201